It makes no sense that a small company that is trying to help humanity can be shorted out of existence or hindered in any way from obtaining financial stability. The next cure for a cancer could be in phase one and never see the light of day for this very reason. Greed sucks. That's your 99% of the wealth for you. I mean how much is enough? 297 million people have to fight over 1% of the crumbs left by 3 million wealthy people. They are not your friends.
Pretty tough for shorts to cover 20 million shares when there are only 1.2 million available to trade. They have to buy and sell the same shares over and over. They look to obtain shares from nervous profitable/losing retail holders. There will probably be some aggressive moves until this drug starts selling. Institutions will continue accumulating the last shares and eventually the price will rise and buying will be costly at which point they will be happy to sell to you if there is limited potential for growth (pipeline). Emerging pharmaceutical plays are not easy money. It takes courage and patience.
Completely different here. It took one year for the DEA to schedule Arena's Belviq. They have competition in the obesity space. This a novel drug that will come with a hefty price tag. Treating obesity is optional and Parkinson's is not. Institutional buying will lock up this stock and those who get out in the short term will be sorry later.